- Home
- IMAB
IMAB
I-MAB
as 07-26-2024 4:00pm EST
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
| Founded: | 2014 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 148.8M | IPO Year: | 2020 |
| Target Price: | $12.25 | AVG Volume (30 days): | 202.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.16 - $2.96 | Next Earning Date: | 08-15-2024 |
| Revenue: | $3,899,013 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -97.23% | Revenue Growth (next year): | N/A |
Latest I-MAB News
IMAB Breaking Stock News: Dive into IMAB Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
I-Mab Names Wei Fu Chairman, Sean Xi-Yong Fu as Interim CEO
PR Newswire
12 days ago
I-Mab Announces Leadership Transitions
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
2 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
2 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
2 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Simply Wall St.
2 months ago
Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns
Compare IMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMAB I-MAB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.